Digest

Diabetes drugs for Alzheimer's disease? Lixisenatide and liraglutide, GLP‐1 agonists licensed for the treatment of type 2 diabetes, have been shown to reverse brain changes in a murine model of Alzheimer's disease (Neuropharmacol 2014;86:241–58). Researchers from the University of Lancaster showed that after 10 weeks' administration to mice in which amyloid plaques had formed, cognitive function was improved and plaque load and microglial activation were reduced. Through the Alzheimer's and Parkinson's Trust North West (www.apt‐northwest.org), they are now seeking additional funding to enable current trials to be completed.
Source: Progress in Neurology and Psychiatry - Category: Neurology Tags: Digest Source Type: research